Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release

References

• Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm. 2011;404:1–9.
   PubMed Web of Science ®Google Scholar
• Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med. 2003;20:886–898.
   PubMed Web of Science ®Google Scholar
• Ozer AY. Alternative applications for drug delivery: nasal and pulmonary routes. In: Mozafari MR, editor. Manomaterials and nanosystems for biomedical applications. Dordrecht, Netherlands: Springer; 2007. p. 99–112.
   Google Scholar
• Senel S. Fundamentals of vaccine delivery in infectious diseases. In: Siepmann J, Siegel RA, Rathbone MJ, editors. Fundamentals and applications of controlled release drug delivery. Berlin, Germany: Springer Science & Business Media; 2011. p. 517–532.
   Google Scholar
• Kestenbaum MG, Vilches AO, Messersmith S, et al. Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Med. 2014;15:1129–1153.
   PubMed Web of Science ®Google Scholar
• Noriega OD, Yarleque Leon SN. Antibiotics by subcutaneous route: a safe and efficient alternative. J Am Med Dir Assoc. 2018;19:553–554.
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588–599.
   PubMed Web of Science ®Google Scholar
• Thomas RJ. Particle size and pathogenicity in the respiratory tract. Virulence. 2013;4:847–858.
   PubMed Web of Science ®Google Scholar
• Haddrell AE, Davies JF, Reid JP. Dynamics of particle size on inhalation of environmental aerosol and impact on deposition fraction. Environ Sci Technol. 2015;49:14512–14521.
   PubMed Web of Science ®Google Scholar
• Herbrink M, Groenland SL, Huitema ADR, et al. Solubility and bioavailability improvement of pazopanib hydrochloride. Int J Pharm. 2018;544:181–190.
   PubMedGoogle Scholar
• Williams HD, Ford L, Han S, et al. Enhancing the oral absorption of kinase inhibitors using lipophilic salts and lipid-based formulations. Mol Pharm. 2018;15:5678–5696.
   PubMedGoogle Scholar
• Frank DS, Matzger AJ. Effect of polymer hydrophobicity on the stability of amorphous solid dispersions and supersaturated solutions of a hydrophobic pharmaceutical. Mol Pharm. 2019;16:682–688.
   PubMed Web of Science ®Google Scholar
• Miao L, Liang Y, Pan W, et al. Effect of supersaturation on the oral bioavailability of paclitaxel/polymer amorphous solid dispersion. Drug Deliv Transl Res. 2019;9:344–356.
   PubMed Web of Science ®Google Scholar
• Oki J, Watanabe D, Uekusa T, et al. Mechanism of supersaturation suppression in dissolution process of acidic drug salt. Mol Pharm. 2019;16:1669–1677.
   PubMedGoogle Scholar
• Price DJ, Ditzinger F, Koehl NJ, et al. Approaches to increase mechanistic understanding and aid in the selection of precipitation inhibitors for supersaturating formulations - a PEARRL review. J Pharm Pharmacol. 2019;71:483–509.
   PubMed Web of Science ®Google Scholar
• Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharm Sci. 2005;94:929–939.
   PubMed Web of Science ®Google Scholar
• McNamara DP, Childs SL, Giordano J. Use of a glutaric acid cocrystal to improve oral bioavailability of low solubility API. Pharm Res. 2006;23:1888–1897.
   PubMed Web of Science ®Google Scholar
• Llinas A, Box KJ, Burley JC, et al. A new method for the reproducible generation of polymorphs: two forms of sulindac with very different solubilities. J Appl Cryst. 2007;40:379–381.
   Web of Science ®Google Scholar
• Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;6:2950–2967.
   Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785–796.
   PubMed Web of Science ®Google Scholar
• Müller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113:151–170.
   PubMed Web of Science ®Google Scholar
• Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm. 2013;453:142–156.
   PubMed Web of Science ®Google Scholar
• Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111:56–64.
   PubMed Web of Science ®Google Scholar
• Kayser O, Olbrich C, Yardley V, et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm. 2003;254:73–75.
   PubMed Web of Science ®Google Scholar
• Blank H, Smith JG. Widespread trichophyton rubrum granulomas treated with griseofulvin. Arch Dermatol. 1960;81:181–191.
   PubMedGoogle Scholar
• Davis B, Child KJ, Tomich EG. Absorption and elimination of griseofulvin from the alimentary tract of the rat. J Pharm Pharmacol. 1961;13:166–171.
   PubMed Web of Science ®Google Scholar
• Rowland M, Riegelman S, Epstein WL. Absorption kinetics of griseofulvin in man. J Pharm Sci. 1968;57:984–989.
   PubMed Web of Science ®Google Scholar
• Ogunbona FA, Smith IF, Olawoye OS. Fat contents of meals and bioavailability of griseofulvin in man. J Pharm Pharmacol. 1985;37:283–284.
   PubMed Web of Science ®Google Scholar
• Venkataram S, Rogers JA. Characteristics of drug-phospholipid coprecipitates II: bioavailability studies of griseofulvin in rats. J Pharm Sci. 1988;77:933–936.
   PubMed Web of Science ®Google Scholar
• Ahmed IS, Aboul-Einien MH. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin. Eur J Pharm Sci. 2007;32:58–68.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Skantze U, Skantze P, et al. A practical guide for the preparation of drug nanosuspensions for preclinical studies – including in vivo case studies. In: Giordanetto F, Early drug development: bridging a preclinical candidate to the clinic. Weinheim, Germany: Wiley; 2018.
   Google Scholar
• Bilgili E, Afolabi A. A combined microhydrodynamics–polymer adsorption analysis for elucidation of the roles of stabilizers in wet stirred media milling. Int J Pharm. 2012;439:193–206.
   PubMed Web of Science ®Google Scholar
• Bilgili E, Li M, Afolabi A. Is the combination of cellulosic polymers and anionic surfactants a good strategy for ensuring physical stability of BCS Class II drug nanosuspensions? Pharm Dev Technol. 2016;21:499–510.
   PubMed Web of Science ®Google Scholar
• Li M, Alvarez PA, Orbe P, et al. Multi-Faceted characterization of wet-milled griseofulvin nanosuspensions for elucidation of aggregation state and stabilization mechanisms. AAPS Pharm Sci Technol. 2018;19:1789–1801.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm. 2011;37:243–251.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Nordmark A, Theilig S, et al. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm. 2011;35:185–192.
   Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Subcutaneous administration of nano- and microsuspensions of poorly soluble compounds to rats. Drug Dev Ind Pharm. 2014;40:511–518.
   PubMed Web of Science ®Google Scholar
• Lindfors L, Forssen S, Skantze P, et al. Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations. Langmuir. 2006;22:911–916.
   PubMed Web of Science ®Google Scholar
• Umlong IM, Ismail K. Micellization of AOT in aqueous sodium chloride, sodium acetate, sodium propionate, and sodium butyrate media: a case study of two different concentration regions of counterion binding. J Coll Interf Sci. 2005;291:529–536.
   PubMed Web of Science ®Google Scholar
• Ghosh I, Bose S, Vippagunta R, et al. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409:260–268.
   PubMed Web of Science ®Google Scholar
• Knieke C, Azad MA, Dave RN, et al. A study of the physical stability of wet media-milled fenofibrate suspensions using dynamic equilibrium curves. Chem Eng Res Des. 2013;91:1245–1258.
   Web of Science ®Google Scholar
• Monteiro A, Afolabi A, Bilgili E. Continuous production of drug nanoparticle suspensions via wet stirred media milling: a fresh look at the rehbinder effect. Drug Dev Ind Pharm. 2013;39:266–283.
   PubMed Web of Science ®Google Scholar
• Mahieu A, Willart J-F, Dudognon E, et al. On the polymorphism of griseofulvin: identification of two additional polymorphs. J Pharm Sci. 2013;102:462–468.
   PubMed Web of Science ®Google Scholar
• Patel PJ, Gajera BY, Dave RH. A quality-by-design study to develop nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes. Drug Dev Ind Pharm. 2018;44:1942–1952.
   PubMed Web of Science ®Google Scholar
• Peltonen L. Practical guidelines for the characterization and quality control of pure drug nanoparticles and nano-cocrystals in the pharmaceutical industry. Adv Drug Deliv Rev. 2018;131:101–115.
   PubMed Web of Science ®Google Scholar
• Krenzlin S, Vincent C, Munzke L, et al. Predictability of drug release from cochlear implants. J Control Release. 2012;159:60–68.
   PubMed Web of Science ®Google Scholar
• Zhu S, Li X, Lansakara-P DSP, et al. A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity. J Pharm Pharmacol. 2013;65:236–242.
   PubMed Web of Science ®Google Scholar
• Fujii Y, Kanamaru T, Kikuchi H, et al. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic activities in its oral dosage form. Int J Pharm. 2011;421:244–251.
   PubMed Web of Science ®Google Scholar
• Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res. 2011;28:1819–1830.
   PubMed Web of Science ®Google Scholar
• Yu SS, Lau CM, Thomas SN, et al. Size- and charge dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int J Nanomed. 2012;7:799–813.
   PubMed Web of Science ®Google Scholar
• Huang RB, Mocherla S, Heslinga MJ, et al. Interactions of nanoparticles in vascular-targeted drug delivery. Mol Membr Biol. 2010;27:312–327.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sun X, Zhang G, et al. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano. 2011;5:1366–1375.
   PubMed Web of Science ®Google Scholar
• Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5–24.
   PubMed Web of Science ®Google Scholar
• Al-Tahami K, Oak M, Singh J. Controlled delivery of basal insulin from phase-sensitive polymeric systems after subcutaneous administration: in vitro release, stability, biocompatibility, in vivo absorption, and bioactivity of insulin. J Pharm Sci. 2011;100:2161–2171.
   PubMed Web of Science ®Google Scholar